Singapore-based insurtech Aktivolabs gains $10M in Series A funding
Aktivolabs, a Singaporean health tech startup, has raised $10 million in a Series A funding round led by Mitsui & Co., Adaptive Capital Partners and Enterprise Singapore's investment arm SEEDS Capital. The investing round was also joined by HH Investments and Govin Capital.
Founded in 2017, the company provides individualised...
Australian company Seer Medical received FDA 510(k) clearance for its at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
Seer Home’s EEG system enables patients to undergo week-long studies at home. Patients wear a device – the Seer Sense – around their shoulders with electrodes connected to the patient’s skull and chest to record brain (EEG) and...
An international study led by Monash University has done what could be the world's first demonstration of an AI model that can predict the optimal anti-seizure medication for newly diagnosed epilepsy patients.
WHAT IT'S ABOUT
The research team has trained a deep-learning prediction model using clinical information from around 1,800 patients in five health care centres in Australia, Malaysia,...
IIT Delhi researchers develop algorithms that detect epileptic seizure source
Researchers from the Indian Institute of Technology – Delhi have come up with a novel algorithm that can localise the epileptogenic zone using a patient's EEG data.
In cases of drug-resistant epilepsies, neurosurgeons have to first determine the exact origin and extent of structural abnormalities in a patient's brain...
Epitel, maker of a wearable electroencephalogram (EEG) system for seizure detection, announced Wednesday it had scored $12.5 million in Series A funding.
The round was led by Catalyst Health Ventures (CHV) and Genoa Ventures, with participation from Dexcom, OSF Ventures, Wavemaker 360, MedMountain Ventures and Salt Lake City Angels.
Before the Series A, Epitel had brought in more than $7.5...
NeuroPace, the maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, announced a $33 million equity raise on Monday. Accelmed Partners led the investment, which was joined by new backers such as Revelation Partners, Soleus Capital and an unnamed strategic investor. Prior backers KCK Group and OrbiMed Advisors also contributed.
Alongside the equity, NeuroPace...
Japanese pharma Eisai Co.'s subsidiary Eisai Inc. is rolling out a new skill on Amazon Alexa developed specifically to target children with Lennox-Gastaut Syndrome (LGS), a rare and severe form of epilepsy.
Dubbed Ella the Jellyfish, the underwater-themed platform includes interactive games such as "Freeze Dance" and "Color Hunt." It also provides users access to music and meditation services. ...
Pharmaceutical company UCB and DEARhealth, a disease management software company, are joining forces on a new initiative aimed at predicting health outcomes for patients with epilepsy. The pair will use DEARhealth’s platform, which integrates artificial intelligence with EHRs.
“This technology will ensure that specific subpopulations within epilepsy will all receive the specific care needed for...
The Embrace2, a seizure monitoring wearable from Boston and Milan-based Embrace, has received an updated FDA clearance that allows it to be used by children ages six and up — the first such device to receive clearance for pediatric use.
"The fact that this is the first clearance of its kind in epilepsy highlights how difficult it is to get robust results with pediatric patients in a clinical...
A new study in the journal Neurology shows that the NightWatch, a connected armband from Leiden, Netherlands-based LivAssured, detected nighttime epileptic seizures 85 percent of the time.
The device has been under development for 20 years by a consortium that includes Kempenhaeghe epilepsy centre, Eindhoven University of Technology, the Foundation for Epilepsy Institutions in the Netherlands (...
